Table 6 Identification of principal enzymes and pathways contributing to the first sPLSDA’s first component and signatures of low score of fibrosis
From: Human liver microbiota modeling strategy at the early onset of fibrosis
Name | Function | |
|---|---|---|
Enzymes | EC:4.1.2.52 | 4-hydroxy-2-oxoheptanedioate aldolase |
EC:3.5.4.1 | Cytosine deaminase | |
EC:3.2.2.4 | AMP nucleosidase | |
EC:4.1.3.3 | N-acetylneuraminate lyase | |
EC:3.1.21.4 | Type II site-specific deoxyribonuclease | |
EC:3.2.1.89 | Arabinogalactan endo-beta-1,4-galactanase | |
EC:3.5.99.6 | Glucosamine-6-phosphate deaminase | |
FAO-PWY | fatty acid &beta,-oxidation I | |
PROTOCATECHUATE-ORTHO-CLEAVAGE-PWY | protocatechuate degradation II (ortho-cleavage pathway) | |
Pathways | GLYCOCAT-PWY | glycogen degradation I (bacterial) |
PWY-6737 | starch degradation V | |
PWY-7323 | superpathway of GDP-mannose-derived O-antigen building blocks biosynthesis | |
COLANSYN-PWY | colanic acid building blocks biosynthesis | |
LACTOSECAT-PWY | lactose and galactose degradation I | |
PWY-6629 | superpathway of L-tryptophan biosynthesis | |
GLCMANNANAUT-PWY | superpathway of N-acetylglucosamine, N-acetylmannosamine and N-acetylneuraminate degradation | |
P441-PWY | superpathway of N-acetylneuraminate degradation | |
PWY0-1533 | methylphosphonate degradation I |